Duaa Durrani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Duaa Durrani has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Aayat Ellahi
Jinnah Sindh Med Univ, Dept Internal Med, Karachi, Pakistan
1 shared publicationAimen Zulfikar
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
1 shared publicationHiba Idrees
Karachi Med & Dent Coll, Dept Internal Med, Karachi, Pakistan
1 shared publicationMahnoor Shaikh
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
1 shared publicationMuhammad Hassan
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
1 shared publicationRahma Idrees
Dow Univ Hlth Sci, Dept Internal Med, Karachi, Pakistan
1 shared publication
Latest Publications
- Open Access
- 23 October 2023
- Published by Medip Academy in International Journal of Scientific Reports
- Vol. 9 (11) , 384-385
The interplay between antidiabetic medications and cancer risk
Diabetes mellitus (DM) refers to a group of metabolic disorders marked by chronic hyperglycemia. Its primary cause usually involves impaired insulin secretion or impaired insulin action. Its prevalence is escalating globally. Type II DM (T2DM) is becoming more common, and it is expected to afflict 7.7% (439 million) of persons aged 20 to 79 by 2030. Diabetes appears to be linked to an increased risk of a variety of cancers, ranging from a 20 to 30% greater risk of breast or colorectal cancer to a 97% increased chance of intrahepatic cholangiocarcinoma or endometrial cancer. Shared risk factors and potential biochemical pathways have prompted investigations into the effect of antidiabetic medications (ADMs) on cancer risk. We intend to investigate the link between diabetes drugs and cancer development.
- 23 October 2023
- Published by Medip Academy in International Journal of Scientific Reports
- Vol. 9 (11) , 384-385
Open AccessThe interplay between antidiabetic medications and cancer risk
Diabetes mellitus (DM) refers to a group of metabolic disorders marked by chronic hyperglycemia. Its primary cause usually involves impaired insulin secretion or impaired insulin action. Its prevalence is escalating globally. Type II DM (T2DM) is becoming more common, and it is expected to afflict 7.7% (439 million) of persons aged 20 to 79 by 2030. Diabetes appears to be linked to an increased risk of a variety of cancers, ranging from a 20 to 30% greater risk of breast or colorectal cancer to a 97% increased chance of intrahepatic cholangiocarcinoma or endometrial cancer. Shared risk factors and potential biochemical pathways have prompted investigations into the effect of antidiabetic medications (ADMs) on cancer risk. We intend to investigate the link between diabetes drugs and cancer development.
- Open Access
- 29 August 2023
- Published by Wolters Kluwer Health in International Journal of Surgery: Global Health
- Vol. 6 (5)
Risk factors and management strategies for atrial fibrillation
Atrial fibrillation (AF) is a cardiac arrhythmia characterised by the irregular and frequently fast depolarization of the atrial myocardium resulting from a disturbance of the usual electrical conduction routes within the atria, which causes disorganised and ineffective atrial contractions. The management of AF involves a multidisciplinary approach that includes identifying and treating underlying risk factors, managing symptoms, and preventing complications. The risk factors for AF include age, hypertension, obesity, diabetes mellitus, valvular heart disease, coronary artery disease, congestive heart failure, alcohol consumption, sleep apnea, and family history. The management strategies for AF include rate control, rhythm control, anticoagulation, left atrial appendage closure, lifestyle modifications, surgical ablation, catheter ablation, cardioversion, and education and support. The choice of management strategy should be tailored to the individual patient’s risk profile, comorbidities, and other factors. Further research is needed to improve our understanding of the pathophysiology of AF and to develop more effective management strategies for this condition.
- 29 August 2023
- Published by Wolters Kluwer Health in International Journal of Surgery: Global Health
- Vol. 6 (5)
Open AccessRisk factors and management strategies for atrial fibrillation
Atrial fibrillation (AF) is a cardiac arrhythmia characterised by the irregular and frequently fast depolarization of the atrial myocardium resulting from a disturbance of the usual electrical conduction routes within the atria, which causes disorganised and ineffective atrial contractions. The management of AF involves a multidisciplinary approach that includes identifying and treating underlying risk factors, managing symptoms, and preventing complications. The risk factors for AF include age, hypertension, obesity, diabetes mellitus, valvular heart disease, coronary artery disease, congestive heart failure, alcohol consumption, sleep apnea, and family history. The management strategies for AF include rate control, rhythm control, anticoagulation, left atrial appendage closure, lifestyle modifications, surgical ablation, catheter ablation, cardioversion, and education and support. The choice of management strategy should be tailored to the individual patient’s risk profile, comorbidities, and other factors. Further research is needed to improve our understanding of the pathophysiology of AF and to develop more effective management strategies for this condition.
- Open Access
- 15 September 2022
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 82, 104663
Vitamin B6: A new approach to lowering anxiety, and depression?
- 15 September 2022
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 82, 104663
Open AccessVitamin B6: A new approach to lowering anxiety, and depression?